Nailesh Bhatt - 02 Dec 2025 Form 4 Insider Report for Hyperliquid Strategies Inc (HYPS)

Role
Director
Signature
/s/ Jason T. Simon, Attorney-in-Fact
Issuer symbol
HYPS
Transactions as of
02 Dec 2025
Net transactions value
$0
Form type
4
Filing time
12 Dec 2025, 11:55:44 UTC
Previous filing
15 Jul 2025
Next filing
11 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bhatt Nailesh Director C/O HYPERLIQUID STRATEGIES INC, 477 MADISON AVENUE, 22ND FLOOR, NEW YORK /s/ Jason T. Simon, Attorney-in-Fact 12 Dec 2025 0001806525

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PURR Common Stock Other +2,082 2,082 02 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Ms. Nailesh Bhatt received 2,082 shares of common stock, par value $0.01 per share, of the Company, in exchange of certain securities of Sonnet Ms. Bhatt held prior to the Closing.